Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy on track to treat first cancer patient by end of 2020

Building work at the Harley Street facility is progressing to schedule, and bosses are confident the ground-breaking LIGHT proton beam therapy system will treat its first patient towards the end of next year
harley street
Proton beam therapy can target cancers more precisely

Advanced Oncotherapy PLC (LON:AVO) remains on track to treat the first cancer patient at its Harley Street facility by the end of 2020.

The AIM company is developing a state-of-the-art, affordable proton beam therapy system called light, which it is currently installing in a town house in central London.

Building work is progressing to schedule, with much of the system due to be in place by the end of this year.

READ: AVO announces positive results from comparative study

As AVO moves nearer to treating the first patient, it has started to gear up its commercial infrastructure with the recent appointment of an experienced chief commercial officer.

Moataz Karmalawy is a “veteran in the commercialisation of PBT technology”, according to research house Hardman & Co, given his previous jobs at Varian and Philips Medical.

“I am very pleased with the progress that we are making to develop a more affordable proton-based radiotherapy system which will ultimately facilitate the wider use of radiation with protons for treating radio-sensitive tumours,” said chief executive Nicolas Serandour.

“Whilst we appreciate that we still have challenges ahead, the achievements we have made further strengthen our dedication and commitment to deliver our game-changing technology to a substantial international market.”

2018 results

For the year ended 31 December 2018, Advanced Onco recorded a loss of £20.2mln (2017: £14.7mln).

At the end of the period, it had £1.0mln of cash in the bank, although it has since secured financing of £12.3ml, including a £10mln debt facility from Credit Suisse.

Shares were flat at 45p on Friday morning.

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

Related Articles

April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use